Michael Kelliher
Directeur/Bestuurslid bij CAPRICOR THERAPEUTICS, INC.
Vermogen: 1 M $ op 31-05-2024
Actieve functies van Michael Kelliher
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CAPRICOR THERAPEUTICS, INC. | Directeur/Bestuurslid | 01-09-2023 | - |
| Independent Dir/Board Member | 01-09-2023 | - | |
| ARDELYX, INC. | Corporate Officer/Principal | 25-03-2024 | - |
Loopbaan van Michael Kelliher
Eerdere bekende functies van Michael Kelliher
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | 01-01-2014 | - |
Opleiding van Michael Kelliher
| University College Cork | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 3 |
| Ierland | 3 |
Operationeel
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| ARDELYX, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Beurs
- Insiders
- Michael Kelliher
- Ervaring
